World News Insights
1-3 Minute Gist
Search, personalize, or simply browse. Follow the world around you from gist and context to insights.
Who we are | Our Credo | Ways of using Lyrarc | FAQ | Send Feedback | First Letter From the Editor
Sign up. It's free and easy to use
Create an account
to personalize your feed of articles and topics.
Browse Articles or use Lyrarc's US patented "Groups" and "Links" for new insights. A Lyrarc Group of Articles on a topic gives insights into particular angles shown in the Group Title. A Lyrarc Link shows more specific insights for 2 articles.
All Topics Links
How Kamala Harris cut migration from Guatemala and other Central American states
07/31/2024
Katie Tobin deputy assistant to the president shows how Kamal Harris cut migration from Guatemala with her action to stabilize Guatemala after the destabilizing of the region by Reagan and Bush through wars started in the region. The achievements to get Guatemalans and Central Americans to stay home compares favorably with the wars and weapons sent to the region under Reagan-Bush that led to gangs taking over San Salvador and young people leaving. Consider $300 million in humanitarian assistance during COVID years, $5 billion in foreign investment lined up to create 250,000 jobs, pulling US AID and IDFC agencies for loans, and arranging for anti-corruption candidate to take over government in Guatemala following elections. It is an exceptional record achieved in a few months trying to undo decades of destabilizing Central America by Republicans Reagan and Bush. Reagan-Bush also destabilized the US with wars in the Persian Gulf, Iraq and Afghanistan, because infrastructure in US was neglected, and manufacturing jobs were shipped overseas under failures of Reagan-Friedman economic theories destroying communities across the US over three decades.
Linked Articles
Opinion | Kamala Harris Made Progress on the Border Crisis
WSJ 07/29/2024
As Republicans Attack Harris on Immigration, Here’s What Her Record ShowsNYTimes.com 07/31/2024
Stephanie Nolan on variants and the struggle with Covid in Africa- reports from frontlines South Africa and Zambia
12/11/2021
Linked Articles
As Vaccines Trickle into Africa, Zambia’s Challenges Highlight Other Obstacles
NYTimes.com 12/11/2021
The Variant Hunters: Inside South Africa’s Effort to Stanch Dangerous MutationsNYTimes.com 12/04/2021
Pfizer BioNTech Vaccine - the history of two Turkish born immigrant scientists in Germany and how it happened
12/02/2020
Linked Articles
How a Couple’s Quest to Cure Cancer Led to the West’s First Covid-19 Vaccine
WSJ 12/02/2020
Pfizer Gets $1.95 Billion to Produce Coronavirus Vaccine by Year’s EndNYTimes.com 07/22/2020
The rapid growth through acquisitions of Teva Pharmaceutical
11/23/2011
Israel's Teva Pharmaceutical is the world's largest maker of generic drugs, followed by Watson Pharmaceuticals and Novarti's Sandoz unit.
Linked Articles
Wall Street Journal 05/08/2012
Former Test-Tube Washer Built Generic-Drug Maker TevaWall Street Journal 11/23/2011
Mexico's war on drug gangs, rising crime and problems of public safety for middle class families- the situation in Cuernavaca, Mexico
10/15/2011
Linked Articles
For Mexico’s middle class, drug war deepens trust deficit - The Washington Post
Washington Post 06/02/2012
Calderon Defends Militarized Response to Mexico's Drug WarNew York Times 10/15/2011
Pfizer and Merck organize R&D using international innovation hubs- 2011-2015
05/02/2011
Efforts to tap into the latest external science at universities and research centers outside company labs is leading pharmaceutical companies to try a different approach to R&D. Pfizer closed its R&D facility in Sandwich, England and opened one in Cambridge. It opened hubs in Boston, La Jolla. Merck has followed this approach with a decision to setup innovaton hubs in Boston, San Francisco, London and Shanghai.
Linked Articles
Merck Plans Radical Overhaul of Drug R&D Unit
Wall Street Journal 12/28/2013
Life Beyond Lipitor for Pfizer ChiefWall Street Journal 05/02/2011
The different approaches of Pfizer and Novartis for new drug research and development in 2009-2015
06/11/2009
Working with smaller R&D budgets and focussing the research on a few areas, collaboration with universities, and other ways to get more out of the R&D dollar.
Linked Articles
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Novartis: Radically Remaking Its Drug BusinessBusinessWeek 06/11/2009
Amgen founder Rathmann and venture startups in the biotech industry
03/16/2009
Rathmann's focus on EPO when Amgen was near bankruptcy in the mid-1980's saved the company. By 1989 Amgen had secured FDA approval for Epogen, a hormone based drug to stimulate the production of red blood cells. This is a rare success in a biotech industry with many failed startup ventures or ventures strugglig with only 6-12 months of cash remaining.
Linked Articles
Cash Dries Up for Biotech Drug Firms
Wall Street Journal 03/16/2009
Amgen's First CEOWall Street Journal 04/23/2012
Vaccine Maker Pfizer and the National Childhood Vaccine Injury Compensation Program.
01/26/2009
The limits to litigation risk for vaccines is one reason for the attractiveness and growing investment in the vaccines development. Its also what Pfizer hopes to develop with the Wyeth acquisition for $68 billion.
Linked Articles
Wall Street Journal 02/23/2009
Pfizer Agrees to Pay $68 Billion for Rival WyethNew York Times 01/26/2009
Changing picture- as Democrats take control of White House and Congress- in the drug industry and health care
11/06/2008
Linked Articles
Medicare, Medicaid Deficits Loom Over Health Priorities
Wall Street Journal 11/06/2008
New FDA Leaders Could Be Tougher on Drug MakersWall Street Journal 11/06/2008
Increasing scruiny in the pharmaceutical industry
05/29/2007
Drug companies come under intense scrutiny with a chairperson of a House Committe with FDA funding oversight comparing the drug industry to the tobacco industry. Scrutiny from medical journals, congress, the media and public of controversial pricing practices, advertising, and presentation of internal study findings.
Linked Articles
Drug Companies Face Political, Scientific Attacks
Wall Street Journal 01/23/2008
Journalistic MalpracticeWall Street Journal 05/29/2007
Doug Parker of U.S. Airways working on his second merger wih American Airlines after difficulties with the first merger
11/20/2006
Linked Articles
US Airways Chief Describes Biggest Challenges in AMR Settlement
Wall Street Journal 12/02/2013
Lessons Learned? How US Airways Would Navigate Merger - WSJ.comWall Street Journal 11/20/2006
Mitch McConnell on the Senate floor "dithering and hesitation have compounded the challenges we face" and the passage of $61 billion aid to Ukraine April 2024
04/26/2024
Mitch McConnell persuades 31 Republican Senators a majority of his caucus to support Ukraine's defense by joining Democrats, working "shoulder to shoulder" with Democrat Pat Schumer to get passage of Ukraine aid legislation in the vote 79 to 18 in April 2024. It comes at a critical moment of the defense of Kharkiv, Ukraine's second largest city, just 25 miles from the border as shown by NYT in April 24 coverage. It is part of the larger effort to secure a peace in Ukraine with the help of India and China as the war drags on for another year.
Linked Articles
Bucking G.O.P. Isolationists, McConnell Was Linchpin in Winning Ukraine Aid
NYTimes.com 04/24/2024
Senate Approves Aid for Ukraine and Israel, Sending It to Biden’s DeskNYTimes.com 04/24/2024
Vaccines that took 40 years to develop- vaccines for malaria and coronavirus
10/17/2021
In a world of short run startups it is important to remember that our lives truly depend on the work done by scientists over decades. The stories of the scientists who developed the vaccine for malaria and the vaccine for mRNA technologies embedded in Pfizer vaccine.
Linked Articles
The Vaccine That Took 40 Years to Make - The Journal. - WSJ Podcasts
WSJ 10/17/2021
Their coronavirus vaccine candidate has made them billionaires. This modest German Turkish couple doesn’t own a car.Washington Post 10/17/2021
A shift in priorities away from drug wars and rising level of violence in Mexico in the presidential elections of 2012
05/20/2012
Linked Articles
U.S. Braces for Mexican Shift in Drug War Focus
New York Times 06/10/2012
Interview with Mexican presidential candidate Enrique Peña Nieto - The Washington PostWashington Post 05/20/2012
Abbott Lab's medical products company and its focus on emerging markets in China and India
10/20/2011
Abbott see the huge potential for infant nutrition and other businesses related to medical products as millons of people join the middle class in China, India, Vietnam and other emerging markets. Nestle is pursuing a similar idea with its acquisition of Pfizer's infant nutrition business which has a large presence in China. With its strong brand name presence, marketing and distribution, and the growing need for better nutrition in these countries Nestle sees huge potential for growth.
Linked Articles
Abbott to Split Into Two Companies
Wall Street Journal 10/20/2011
Abbott Looks to Consumer for GrowthWall Street Journal 05/03/2012
Pfizer's focus on its core pharmaceutical business in 2011-2015
05/02/2011
Rockoff's interview with Pfizer CEO, Ian Read, in which Read describes his strategy of focussing on new drug development and locating closer to hubs with large universities and research centers such as La Jolla, Cambridge, Massachusetts, and Cambridge, England. Pfizer sold its infant nutrition business to Nestle as part of this plan.
Linked Articles
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Life Beyond Lipitor for Pfizer ChiefWall Street Journal 05/02/2011
Research and Development (R&D) approaches of pharmaceutical companies Pfizer and Glaxo with smaller budgets and smaller units
07/01/2010
Linked Articles
Pfizer Profit Declines 19% After Loss of Lipitor Patent
New York Times 05/01/2012
Glaxo Tries Biotech Model to Spur Drug InnovationsWall Street Journal 07/01/2010
As capital markets shun small biotech startups large drug companies raise money for acquisitios and mergers.
03/16/2009
Drug companies have $155 billion they plan to use for mergers and acquisitions and are tapping the bond markets for funds. Meantime small biotech startups are running short of cash in large numbers. Will this squeeze innovation and new products as startups wither and the mergers run into problems?
Linked Articles
Drug Firms Bet Big on High-Risk Deals
Wall Street Journal 03/17/2009
Cash Dries Up for Biotech Drug FirmsWall Street Journal 03/16/2009
Astra Zeneca suppresses information about the link between best selling psychiatric drug Seroquel and diabetes.
02/27/2009
Now disclosed court documents show that AstraZeneca carefully suppressed information about the links between Seroquel and diabetes from a 2000 study from one of its drug safety experts.
Linked Articles
AstraZeneca Papers Raise Seroquel Issues
Wall Street Journal 02/27/2009
AstraZeneca Drug's Effectiveness QuestionedWall Street Journal 02/28/2009
Another misstep by automakers management was the failure to win public support as they missed the changes coming over the country.
11/18/2008
The falling clout of the Detroit automakers as the nation changed and things changed but the automakers dug in their heels into the status quo.
Linked Articles
Clout Has Plunged for Automakers and Union, Too
New York Times 11/18/2008
Bridge Loan to NowhereWall Street Journal 12/06/2008
Drug cartels emerging in Afghaistan.
07/27/2008
The UN OFfice of Drugs and Crime ses the growth of drug cartels in Afghaistan as 10,000 tons of drugs from the opium crop have been stockpiled inside Afghistan and are controlled by narco-gangs. This is estimated as 2 years of world demand. This as efforts to curb opium growing have reduced the land devoted to the crop by 22% and reduced the crop by 10%.
Linked Articles
U.N. Sees Afghan Drug Cartels Emerging
New York Times 09/02/2009
Is Afghanistan a Narco-State?New York Times 07/27/2008
Doug Parker of US Airways and the proposed merger with American Airlines (AMR) in 2012
11/20/2006
Linked Articles
Lessons Learned? How US Airways Would Navigate Merger - WSJ.com
Wall Street Journal 11/20/2006
Steven Pearlstein: Two can play the airline bankruptcy game - The Washington PostWashington Post 04/29/2012
Aggressive television advertising by Pfizer and Glaxo Smithkline
10/25/2006
Linked Articles
How Glaxo Marketed a Malady to Sell a Drug - WSJ.com
Wall Street Journal 10/25/2006
Glaxo to Pare Ads on U.S. TelevisionWall Street Journal 01/09/2009
We took a different way to help millions around the world build educated informed mindsets that affects and shapes their lives. For a future that is open, global and digital, with everyone having access to high quality information. We believe in the renewal of America, renewal of Europe, the renewal of India, the rest of Asia, Latin America and Africa. The renewal of our supply chains, health, education, infrastructure, as we rebuild our countries after the pandemic. Literacy and knowledge we believe cannot thrive and grow in a world of web bots, web crawlers, or AI. This requires human curiosity, human learning, and human imagination. We take as inspiration the saying- “One has to be free, and as broad as sky. One has to have a mind that is crystal clear, only then can truth shine in it.” Every contribution whether big or small is precious- in this crisis and ahead.
Support Lyrarc from as small as $1
Terms and Conditions | Copyright Policy | Privacy Policy | Contact Us